Atrium Therapeutics, Inc. Common Stock (RNA) Stock Price

Atrium Therapeutics, Inc. Common Stock Price

NYSE·CLOSED
6.43
​
Market closed

Over the last 14 years Atrium Therapeutics, Inc. Common Stock grew revenue by 3.6% annually, reaching 18.62 M USD. For Atrium Therapeutics, Inc. Common Stock, the net margin of -411.9% is up versus -1,258.5% a few years ago. The consensus 12-month price target for Atrium Therapeutics, Inc. Common Stock is 25.00 USD, about 288.8% above where the stock trades today. Of 8 analysts, 7 rate the stock a buy — an overall Buy consensus.

Atrium Therapeutics, Inc. Common Stock stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Atrium Therapeutics, Inc. Common Stock business model & stock analysis

Atrium Therapeutics, Inc. develops RNA therapeutics for cardiomyopathies, focusing on ATR 1072 targeting PRKAG2 for PRKAG2 syndrome and ATR 1086 targeting PLN for PLN cardiomyopathy. The company collaborates with Bristol-Myers Squibb Company and Eli Lilly and Company through a research collaboration and license agreement. It operates in the biopharmaceutical sector with a pipeline targeting genetic and cardiac diseases. The company's revenue model is based on the development and potential commercialization of its RNA-based therapies. ATR 1072 and ATR 1086 are in development stages, with Bristol-Myers Squibb and Eli Lilly as key partners. These partnerships likely involve milestone payments and royalties upon successful development and market entry. Atrium Therapeutics' target segments include patients with PRKAG2 syndrome and PLN cardiomyopathy, as well as broader genetic and cardiac disease populations. The company's primary buyers are pharmaceutical and biotech partners like Bristol-Myers Squibb and Eli Lilly, who fund research and share commercialization rights through their agreements.

Frequently asked questions about Atrium Therapeutics, Inc. Common Stock

Analysts currently set an average price target of 25.00 USD for the Atrium Therapeutics, Inc. Common Stock stock (median: 25.00 USD), implying +285.8 % versus the latest price. The consensus is based on 8 analyst ratings.

8 analysts currently rate the Atrium Therapeutics, Inc. Common Stock stock: 7 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Atrium Therapeutics, Inc. Common Stock to generate revenue of 35.02 M USD and earnings per share of -4.29 USD.

Converted at the current exchange rate, the Atrium Therapeutics, Inc. Common Stock share trades at 5.86 EUR (6.43 USD).

The expected revenue of Atrium Therapeutics, Inc. Common Stock is 35.02 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Atrium Therapeutics, Inc. Common Stock is -73.48 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Atrium Therapeutics, Inc. Common Stock is currently -1.50. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Atrium Therapeutics, Inc. Common Stock stock.

The price-to-sales ratio (P/S) of Atrium Therapeutics, Inc. Common Stock is currently 3.14. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Atrium Therapeutics, Inc. Common Stock stock.

The Eulerpool Quality Score for Atrium Therapeutics, Inc. Common Stock is 5/10.

The ISIN of Atrium Therapeutics, Inc. Common Stock is US04965N1046. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Atrium Therapeutics, Inc. Common Stock is RNA. The ticker symbol is used to trade Atrium Therapeutics, Inc. Common Stock shares on the stock exchange.

Fair ValueTerminal
6.75 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Jun 28, 2013
ISIN
US04965N1046
Cusip
N71546100
Market capitalization
109.99 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-1.50
P/Ee 2027
-1.00
P/Ee 2028
-1.04
P/Ee 2029
-1.40
P/Ee 2030
-1.45
P/S
P/Se
3.14
EV/EBIT
2.04
P/B Ratio
0.53
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-36.35 %
Last updated Nov 19, 2026, 3:45 AM